CGP’s 2024 Interim Report Shows Robust Growth in Revenues and Profits, Highlighting R&D Focus
HONG KONG—China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has released its interim...
HKG: 0512
China’s SAMR Proposes Antitrust Guidelines to Regulate Pharmaceutical Industry
The State Administration for Market Regulation (SAMR) in China has unveiled a draft proposal for...
China Grand Pharmaceutical Expands with Mitsubishi Tanabe Pharma and Baiji Pharma Acquisitions
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the completion of...
Grand Pharmaceutical Gets Nod for Phase II Sepsis Study of STC3141 in China
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced that it has...
Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...
CGP’s GPN00884 Myopia Drug Enters Phase I Clinical Trial with First Patient Dosed
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the commencement of...
Grand Pharma Receives NMPA Approval for Global Phase III Study of RDC ITM-11 in GEP-NETs
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...
China Grand Pharmaceutical Reports Robust 2023 Revenues and Pipeline Advancements
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has reported its financial results...
China Grand Pharmaceutical Receives FDA Approval for Post-Surgical Ophthalmic Drug GPN00833
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has...
China Grand Pharmaceutical Gets NMPA Green Light for mRNA Cancer Vaccine ARC01 Phase I Study
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has...
China Grand Pharma to Acquire 63% Stake in Duoputai for RMB 442 Million
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to...
China Grand Pharmaceutical to Acquire Majority Stake in Mitsubishi Tanabe’s Tianjin Subsidiary
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to...
China Grand Pharmaceuticals Secures Distribution of Sirtex’s SIR-Spheres for Liver Cancer
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) announced that its subsidiaries, Beijing...
China Grand Pharma’s Lava Liquid Embolic Agent Officially Commercialized in the US
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the official commercialization...
China Grand Pharma Initiates Phase III Trial for GPN00833 in Cataract Surgery Recovery
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced a significant milestone...
China Grand Pharmaceutical Reports H1 2023 Revenues and Pipeline Progress
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has released its financial report...
Grand Pharmaceutical’s GSP301 NS Meets Primary Endpoint in Phase III SAR Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Phase III study (GSP...
Grand Pharmaceutical Receives NMPA Approval for Generic Carbaglu for Hyperammonemia Treatment
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...
Grand Pharmaceutical Group Initiates Phase I Study for Sepsis Treatment APAD
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the enrollment and dosing of the...
Telix Pharmaceuticals and Grand Pharma Initiate Phase III Trial for Illucix in China
Australian biotechnology company Telix Pharmaceuticals Ltd (ASX: TLX) and its China market partner, Grand Pharmaceutical...